好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Correlation between Magnetization Transfer Ratio and Functional Status in Multiple Sclerosis patients
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-046
To evaluate the correlation between magnetic transfer ratio (MTR) and disability measures in relapsing remitting MS patients (RRMS).  

Magnetization transfer ratio (MTR) is a measure of demyelination and tissue destruction in MS.  MTR values are not only useful to detect structural changes but if found to correlate with functional decline, may help further quantify disease severity in MS.

Twenty-one patients were included in this cross sectional study. We attempted to trend functional disease progression against MTR changes in gray matter (GM), normal appearing white matter (NAWM) and lesional WM. We compared MTR values from WM, lesional WM and GM to functional scales at baseline and Year 1. We used the Expanded Disability Status Scale (EDSS), and the multiple sclerosis functional composite (MSFC) which consists of the paced auditory serial addition test -3 (PASAT-3), 9 hole peg test (9 HPT) and 25 foot walk test. A 2- tailed Pearson Correlation analysis was used to compare the MTR WM values to the functional scales.

Our results showed that GM MTR has a significant inverse relationship with upper extremity function measured by the 9HPT (-0.475, p 0.029) and lesional WM MTR is associated with cognitive ability and processing of information measured by PASAT-3 (-0.544, p-0.016). EDSS marginally correlates with WM and GM MTR (-0.046, p0.043) but not with lesional MTR. No such relationship was found with the 25 foot walk test.

MTR values can be useful to further quantify functional progression of MS when used in combination with PASAT -3 and 9HPT as well as with EDSS but not with 25 foot timed walk. GM MTR and lesional MTR might be potential biomarkers of upper extremity function and cognitive processing respectively. Further studies with larger samples are needed to validate our results.

Authors/Disclosures
Ali Ebrahim, MD (GVMH)
PRESENTER
Dr. Ebrahim has nothing to disclose.
Zainab Alalawi, MD No disclosure on file
Kalyan Yarraguntla, MD (University Health Center) Dr. Yarraguntla has nothing to disclose.
Fen Bao Fen Bao has nothing to disclose.
Mohammed Alhaidar, MD Dr. Alhaidar has nothing to disclose.
Samuel Lichtman-Mikol, BA (Wayne State University) Mr. Lichtman-Mikol has nothing to disclose.
Sara Razmjou-Schwarz, MD (Mclaren Macomb hospital) No disclosure on file
Navid Seraji-Bozorgzad, MD (University of Michigan Medicine-Neurology) No disclosure on file
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine) Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.